Bayer $BAYN.DE
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS19
PHASE 3 / 2-310
RECRUITING9
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO50%
Delay Index: of 16 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +9.4 months). See all sponsors →
Open Bayer on the live radar map → 📅 $BAYN.DE readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PATENT-CHILD NCT02562235 |
P3 | Active, not recruiting | Hypertension, Pulmonary | 24 | 2020-03-07 (+15 mo) |
| OASIS-4 NCT05587296 |
P3 | Active, not recruiting | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Hot Flashes | 474 | 2024-01-29 |
| SCOUT NCT02637687 |
P1/2 | Active, not recruiting | Solid Tumors Harboring NTRK Fusion | 154 | 2024-07-20 (+86 mo) |
| CAMELLIA-HCM NCT07023341 |
P3 | Active, not recruiting | Obstructive Hypertrophic Cardiomyopathy | 36 | 2026-07-14 (-2 mo) |
| FIONA NCT05196035 |
P3 | Active, not recruiting | Chronic Kidney Disease; Proteinuria | 219 | 2027-04-10 (+9 mo) |
| ARASTEP NCT05794906 |
P3 | Active, not recruiting | Biochemically Recurrent Prostate Cancer | 985 | 2027-07-30 (+6 mo) |
| SOHO-02 NCT06452277 |
P3 | Recruiting | Advanced Non-small Cell Lung Cancer, HER2 Mutation | 444 | 2027-10-28 (+17 mo) |
| ASSESS NCT07211685 |
P2 | Active, not recruiting | Alport Syndrome | 60 | 2027-11-29 (-8 mo) |
| Regorafenib (Stivarga, BAY73-4506) NCT06246643 |
P2 | Active, not recruiting | Solid Malignant Tumors | 13 | 2028-04-27 (+24 mo) |
| DARO ROLL OVER NCT04464226 |
P3 | Active, not recruiting | Cancer | 774 | 2028-06-26 (+44 mo) |
| FIONA OLE NCT05457283 |
P3 | Recruiting | Chronic Kidney Disease; Proteinuria | 100 | 2028-08-07 (+6 mo) |
| CHINANEO NCT07450599 |
P2 | Recruiting | High-risk Localized Prostate Cancer | 250 | 2028-10-15 |
| BAY2927088_formulation A NCT05099172 |
P1/2 | Recruiting | Advanced Non-small Cell Lung Cancer; EGFR Mutation | 430 | 2028-12-01 (+35 mo) |
| panSOHO NCT06760819 |
P2 | Recruiting | Advanced Solid Tumors; HER2 Mutation | 111 | 2029-02-02 (+24 mo) |
| AB-1005 NCT07566429 |
P2 | Not yet recruiting | Parkinson Disease | 8 | 2029-06-15 |
| BAY 3713372 NCT06914128 |
P1/2 | Recruiting | MTAP-deleted Solid Tumors | 450 | 2029-06-18 |
| FIORE NCT07188805 |
P3 | Recruiting | Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric) | 111 | 2029-11-30 |
| CARDIOVERT NCT07625215 |
P2 | Recruiting | Atrial Fibrillation | 360 | 2030-05-16 |
| FIORELLO NCT07192952 |
P3 | Recruiting | Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric) | 117 | 2030-12-30 |